Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ocular Therapeutix (OCUL)
NASDAQ:OCUL
Holding OCUL?
Track your performance easily
OCUL Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.00 - $11.31
Previous Close$8.76
Volume1.48M
Average Volume (3M)1.47M
Market Cap
$1.37B
Enterprise Value$981.07M
Total Cash (Recent Filing)$459.69M
Total Debt (Recent Filing)$74.89M
Price to Earnings (P/E)―
Beta1.64
Next Earnings
Nov 04, 2024EPS Estimate
-$0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.35
Shares Outstanding155,921,685
10 Day Avg. Volume726,717
30 Day Avg. Volume1,468,892
Standard Deviation0.27
R-Squared0.06
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)3.62
Price to Sales (P/S)22.79
Price to Cash Flow (P/CF)-14.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue16.06
Enterprise Value/Gross Profit18.45
Enterprise Value/Ebitda-8.24
Forecast
1Y Price Target
$15.67Price Target Upside73.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Ocular Therapeutix News
PremiumCompany Announcements
Ocular Therapeutix Appoints Donald Notman as COO
Bulls Say, Bears Say
Bulls Say
Enrollment ProgressSOL-1 enrollment continues to accelerate and exceed management’s expectation, with 60 sites activated and 151 patients enrolled.
Financial StabilityThe company ended 2Q24 with $460M in cash, which management expects to be sufficient runway into 2028, beyond anticipated readouts in both SOL-1 and SOL-R.
Regulatory ApprovalFDA written feedback says the SOL-R study is an adequate registrational study.
Bears Say
Clinical Trial ResultsResponse rates in HELIOS came in below the approved anti-VEGFs, which is viewed as an overreaction considering axpaxli’s differentiated durability profile and management’s commitment to Phase 3.
Investor ExpectationsSome signs of efficacy, missing investor expectations, but caution is advised in reading too much into the small study.
Stock PerformanceOCUL shares are down ~12% after response rates in HELIOS came in below the approved anti-VEGFs.
---
Ownership Overview
14.33% Insiders
8.82% Mutual Funds
67.28% Other Institutional Investors
9.57% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
OCUL FAQ
What was Ocular Therapeutix’s price range in the past 12 months?
Ocular Therapeutix lowest stock price was $2.00 and its highest was $11.31 in the past 12 months.
What is Ocular Therapeutix’s market cap?
Currently, no data Available
When is Ocular Therapeutix’s upcoming earnings report date?
Ocular Therapeutix’s upcoming earnings report date is Nov 04, 2024 which is in 46 days.
How were Ocular Therapeutix’s earnings last quarter?
Ocular Therapeutix released its earnings results on Aug 07, 2024. The company reported -$0.26 earnings per share for the quarter, missing the consensus estimate of -$0.221 by -$0.039.
Is Ocular Therapeutix overvalued?
According to Wall Street analysts Ocular Therapeutix’s price is currently Undervalued.
Does Ocular Therapeutix pay dividends?
Ocular Therapeutix does not currently pay dividends.
What is Ocular Therapeutix’s EPS estimate?
Ocular Therapeutix’s EPS estimate is -$0.24.
How many shares outstanding does Ocular Therapeutix have?
Ocular Therapeutix has 155,921,690 shares outstanding.
What happened to Ocular Therapeutix’s price movement after its last earnings report?
Ocular Therapeutix reported an EPS of -$0.26 in its last earnings report, missing expectations of -$0.221. Following the earnings report the stock price went up 6.084%.
Which hedge fund is a major shareholder of Ocular Therapeutix?
Among the largest hedge funds holding Ocular Therapeutix’s share is Perceptive Advisors LLC. It holds Ocular Therapeutix’s shares valued at 23M.
---
Ocular Therapeutix Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.67 (73.15% Upside)
$15.67 (73.15% Upside)
Blogger Sentiment
Bullish
OCUL Sentiment 88%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 47.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $204.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
151.72%
12-Months-Change
Fundamentals
Return on Equity
-72.67%
Trailing 12-Months
Asset Growth
321.92%
Trailing 12-Months
Company Description
Ocular Therapeutix
Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline include Dextenza, OTX-TP, and OTX-TIC . The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.
---
OCUL Earnings Call
Q2 2024
0:00 / 0:00
---
OCUL Stock 12 Month Forecast
Average Price Target
$15.67
▲(73.15% Upside)
Technical Analysis
EyePoint Pharmaceuticals
―
Kala Pharmaceuticals
―
Ocuphire Pharma
―
vTv Therapeutics
―
Best Analysts Covering OCUL
1 Year
1 Year Success Rate
14/21 ratings generated profit
1 Year Average Return
+39.54%
reiterated a buy rating last month
Copying Yi Chen's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +39.54% per trade.
---